Irinotecan (Camptosar®) is used, or under evaluation, in a broad spectrum of solid tumors, and is often prescribed for treating patients with metastatic cancer of the colon or rectum, especially when 5-fluorouracil treatment has not been entirely successful. Severe toxicity (eg, grade 4 neutropenia) is commonly observed in cancer patients receiving irinotecan who carry the UGT1A1*28 allele, also called TA. This test result will provide valuable information to physicians prior to initiating or modifying treatment or supplementing treatment with additional drugs. UGT1A1 variants have also been reported in patients with disorders of bilirubin metabolism, such as Crigler-Najjar Types I and II, as well as Gilbert syndrome. Between 80% to 100% of Caucasian patients with Gilbert syndrome are reported to have either one or two copies of UGT1A1*28. G71R (*6), a UGT1A1 variant reported in Asian patients with Gilbert syndrome, is not detected by this assay.

Lavender (EDTA), 10mL

Immediately after collection, mix sample thoroughly by gentle inversion, 8 - 10 times, to prevent clotting

Lavender (EDTA), 10mL

Yellow ACD (A or B)

Yellow ACD (A or B)

Molecular Medicare Billing Request

Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.

Ambient (preferred) - 7 days

Refrigerated - 1 month

Frozen - 2 years

• Hemolysis
• Quantity not sufficient for analysis
• Improper container/anticoagulant

Polymerase chain reaction (PCR) and capillary electrophoresis

An interpretive report will be provided

Medical necessity

Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.

Molecular Medicare Billing Request